What is DVAX's current stock price?

DVAX (Dynavax Technologies Corporation) is currently trading at $15.50 with a market cap of $1.82B.

What sector is Dynavax Technologies Corporation in?

Dynavax Technologies Corporation (DVAX) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.

Is DVAX a good stock to buy?

Analysts have a Hold consensus on DVAX with a price target of $27.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

DVAX Dynavax Technologies Corporation

Healthcare

$15.50+0.00%ClosedMarket Cap: $1.82B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.40

P/S

5.51

EV/EBITDA

-75.83

DCF Value

$-22.27

FCF Yield

4.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

83.2%

Operating Margin

3.2%

Net Margin

-13.1%

ROE

-8.1%

ROA

-4.6%

ROIC

1.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q3 null	$94.9M	$26.9M	$—
Q2 null	$95.4M	$18.7M	$—
Q1 null	$68.2M	$-96.1M	$—
Q4 null	$72.0M	$7.0M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$27.00

Target (Median)

$29.00

Target Range

$20.00 - $32.00

0 Strong Buy1 Buy1 Hold1 Sell0 Strong Sell

William BlairMarket Perform

2025-12-24

JMP SecuritiesMarket Outperform

2025-08-22

Trading Activity

Insider Trades

View All

Deep Track Biotechnology Master Fund, Ltd.10 percent owner

SellWed Feb 11

Spencer Ryandirector, officer: CEO and Director

SellTue Feb 10

Spencer Ryandirector, officer: CEO and Director

SellTue Feb 10

Spencer Ryandirector, officer: CEO and Director

SellTue Feb 10

Spencer Ryandirector, officer: CEO and Director

SellTue Feb 10

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

Exchange

—

Beta

0.93

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Peers

EVO